Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
Phase 2
Not yet recruiting
- Conditions
- Diabetic Kidney Disease (DKD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT06962098
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
Phase 2
Recruiting
- Conditions
- Contrast Induced Acute Kidney Injury
- Interventions
- Drug: PlaceboDrug: Isuzinaxib (APX-115)
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT05758896
- Locations
- 🇺🇸
Sarkis Clinical Trials, Ocala, Florida, United States
🇰🇷Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
🇰🇷Inje University Ilsan Paik Hospital, Goyang, Korea, Republic of
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04880109
- Locations
- 🇺🇸
Alternative Research Associates, LLC, Hialeah, Florida, United States
🇺🇸Anne Arundel Medical Center, Baltimore, Maryland, United States
🇺🇸Millennium Physicians Group, Houston, Texas, United States
Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
Phase 2
Completed
- Conditions
- Nephropathy, DiabeticDiabetic NephropathiesDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04534439
- Locations
- 🇧🇬
Hadzhi Dimitar, Sofia, Bulgaria
🇧🇬Pleven, Pleven, Bulgaria
🇧🇬Diagnostic-consultative centre I, Sliven, Bulgaria
Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- SafetyHealthy
- Interventions
- Other: Metabolic probe with or without APX-115
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT03694041
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
© Copyright 2025. All Rights Reserved by MedPath